Atlas Trials

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

Clinical trial NCT06015464 · UNKNOWN

Trial details

NCT number
NCT06015464
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Study type
OBSERVATIONAL
Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
Start date
2023-09-01
Primary completion
2024-12-30
Enrollment
81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.